N.J. pharma leads rebellion against feds’ controversial discount drug program – NJ.com

Johnson & Johnson logos in front of their office building located in Raritan.Paul Zimmerman | For NJ Advance Media
New Jersey’s pharmaceutical industry is at the forefront of a rebellion against a federal discount drug program intended for hospitals and clinics that serve low-income patients.
Johnson and Johnson, the world’s largest drug maker, this month joined 15 other companies to propose or set limits in a direct challenge to mandatory discounts under the federal law, called 340B.
Note to readers: if you purchase something through one of our affiliate links we may earn a commission.
Registration on or use of this site constitutes acceptance of our User Agreement, Privacy Policy and Cookie Statement, and Your California Privacy Rights (User Agreement updated 1/1/21. Privacy Policy and Cookie Statement updated 5/1/2021).
Cookie Settings
© 2022 Advance Local Media LLC. All rights reserved (About Us).
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Advance Local.
Community Rules apply to all content you upload or otherwise submit to this site.
Ad Choices LogoAd Choices

source

Add a Comment

Your email address will not be published.